Escape Therapeutics, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 3, 2027The maintenance fee for Method of cell transplantation into a human recipient (US 9,173,904) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Mesenchymal stem cells with enhanced immunosuppressive capability (US 10,576,105) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Peptide tyrosinase inhibitors and uses thereof (US 9,320,698) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,173,904 | Method of cell transplantation into a human recipient In force · From the USPTO record | In force | From the USPTO record | |
| US 8,647,871 | Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,822,215 | Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,347,045 | Differentiation of mesenchymal stem cells into fibroblasts In force · From the USPTO record | In force | From the USPTO record | |
| US 9,382,514 | Compositions comprising mesenchymal stem cell-derived fibroblasts In force · From the USPTO record | In force | From the USPTO record | |
| US 8,911,723 | Hybrid hydrogel scaffold compositions and methods of use In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 9,320,698 | Peptide tyrosinase inhibitors and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,053,670 | Enhanced differentiation of mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,554,746 | System for evaluating skin treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 9,567,368 | Peptide tyrosinase activators In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 3 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 4 no status recorded